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A Ab bs st tr ra ac ct t    Despite the existence of Hepatitis B vaccination, hepatitis B virus (HBV) 
infection is still prevalent worldwide and accounts for significant morbidity 
and mortality.  It is encouraging that majority of patients do recover from the 
acute infection, however, those that progress to chronic disease state is at 
great risk of developing complications such as hepatocellular carcinoma, 
cirrhosis and liver failure.  Hepatitis B virus infection can be influenced by 
many factors such as host immune status, age at infection, and level of viral 
replication.  The discovery about the existence of various genotypes and its 
association with different geographic distribution as well as the knowledge 
regarding mutant species has aid us in better understanding the nature of 
HBV infection and in delivering better care for patients.  It is especially 
important to recognize those individuals with HBeAg-negative chronic HBV 
as they have a poorer prognosis compare with their counterparts, HBeAg-
positive.  Tremendous progress has been made over the years in 
understanding the behavior and clinical course of the disease; however, the 
natural history of HBV is complex and we still have much to explore and 
learn.    
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1.  Background 
Despite the presence of hepatitis B vaccine, new HBV infection remains common.  Primary HBV infection in susceptible 
individuals can be either symptomatic or asymptomatic, the latter being often the case, especially in young individuals; but rarely, 
fulminant hepatitis can develop during acute phase.  Most primary infections are self-limited with clearance of virus and 
development of immunity.  However, an estimated 3% to 5% of adults and up to 95% of children develop chronic HBV infection.  
Persistent infection can also be either symptomatic or asymptomatic; those with elevated liver chemistries and abnormal biopsies are 
termed as having chronic hepatitis B and those with normal studies are labelled as chronic HBV carriers.  Long-term infection 
increases risk of developing cirrhosis and HCC. 
2.  HBV Genotypes and Mutants  
DNA sequence of HBV isolates has shown the existence of 8 viral genotypes A-H and these varies in geographic distribution 
(Table 1). Genotype A is found primarily in North America, Northern Europe, India, and Africa. Genotype B and C are common in 
Asia; genotype D, in southern Europe, the Middle East, and India; genotype E, in West Africa and South Africa; genotype F, in 
South and Central America; genotype G, in the United States and Europe [1].  Genotype H was recently identified in individuals 
from Central America and California [2].  Several genotypes may be associated with the severity of the disease but the relationship 
between the genotype and the developing hepatocellular carcinoma has not been established.  In China and Japan, some studies have 
found more severe liver disease to be associated with genotype C than compare with genotype B [3], other studies have found no 
such association [4,5].  There is some evidence that shows HBeAg seroconversion occurs at a younger age among individuals 
infected with genotype B [3, 5, 6].  Genotype D has been associated with anti-HBe-positive chronic hepatitis B infection in the 
Mediterranean region [7].   
Table 1. Genotypes of HBV and Geographic Distribution 
 
HBV has a reported mutation rate of 10 times greater compare with other DNA 
viruses.  These mutations can occur naturally as well as due to selective pressure 
from antiviral therapy.  There are five clinically relevant HBV types: wild-type 
HBV, precore mutants, core promoter mutants, tyrosine-methionine-aspartate-
aspartate (YMDD) mutants induced by lamivudine treatment, and asparagine to 
threonine (rtN236T) mutants recently identified in patients with adefovir treatment.  
In a study carried out in the United States, the precore variant of HBV was rarely 
found in association with genotype A, but it was found in almost 50% of those with 
genotype C and in >70% of individuals with genotype D.  Those with precore variant 
and core promoter mutations had higher HBV DNA levels in sera than those persons 
without these mutations.  It is observed that flares in chronic HBV have been 
associated with increases in concentrations of precore mutation in proportion to wild-
type HBV.  Exacerbations have been thought to subside with time when the genetic 
heterogeneity disappears and patients become exclusively infected with precore HBV 
[8].  During the treatment of chronic hepatitis B by lamivudine, drug resistance may develop, which is mediated by point mutations 
with the YMDD motif at the catalytic center of the viral reverse transcriptase. With increase in the mutant viral load, patients can 
sustain further liver injury.  The YMDD mutant level will decrease after stopping lamivudine.  Viral mutation also occurs in patients 
on adefovir treatment during their second year therapy at the rate of 2.5%.  The mutation has been reported as asparagine to 
threonine mutation (rtN236T), downstream of the YMDD motif. It is not clear yet if rtN236T mutant can induce further liver 
damage. 
3.  HBV Transmission and Vaccination 
Perinatal or horizontal infection early in childhood are the main routes of HBV transmission in high endemic region, such as 
Asia, Africa, Pacific Islands and the Arctic and the rate of HBsAg positivity ranges from 8% to 15%.  In the low endemic area, such 
as Western countries, HBV is predominantly a disease of adolescents and adults as a result of high risk sexual behavior or injection 
drug use and the rate of HBsAg positivity is less than 2% [9].  HBV infection frequently is waxing and waning, it goes through 
alternating cycles of replicative and non-replicative phases. 
Since the availability of hepatitis B vaccination in 1982, it has had some dramatic impact on the outcome of liver disease.  For 
example, in Alaska, the proportion of HBV carriers who were HBsAg positive in the population declined from 35% to 3% in 15 
years after the introduction of the vaccination program in newborns and the completion of a mass vaccination catch up program [10].  
In Taiwan, the universal hepatitis B vaccination in newborns has both dramatically decreased prevalence of HBsAg as well as 
incidence of HCC in this age group.  
4.  Stages of HBV Infection 
An individual can develop hepatitis B infection that is acute and achieve complete immune clearance of virus yielding lifelong 
immunity; however, an alternate fate of the host is the development of chronic hepatitis B.  There are three stages of HBV infection 
based on viral-host interaction, namely, the immune tolerant phase, the immune clearance phase, and the inactive carrier phase with 
or without reactivation (Fig 1.).  After acute infection of HBV, some patients may remain HBeAg positive with high levels of serum 
HBV DNA, little or no symptoms, normal ALT levels and minimal histological activity in the liver, this phenomenon is known as 
the immune tolerance phase.  This phase is typical of infection in children and young adults.  It usually lasts for 2-4 weeks, but can 
last for years in those who acquired the infection during the perinatal period [11].  Individuals in this group are highly contagious 
and can transmit HBV easily. When the tolerogenic effect is lost during the immune tolerant phase, immune-mediated lysis of 
infected hepatocytes become active and patients enter the second stage defined as immune clearance phase, the HBV DNA level 
Genotype Geographic  Distribution 
A  Africa, India, Northern 
Europe, United States 
B Asia,  United  States 
C Asia,  United  States 
D India,  Middle  East, 
Southern Europe, United 
States 
E  West and South Africa 
F  Central and South America 
G Europe,  United  States 
H  Central and South America, 
California in United States Int. J. Med. Sci. 2005 2(1) 
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decreases and ALT level increases. The duration of clearance phase lasts from months to years. This is followed by the carrier stage, 
in which seroconversion of HBeAg to HBeAb occurs, HBV DNA becomes non-detectable or at low level and ALT is usually 
normal, reflecting very low or no replication of HBV and mild or no hepatic injury.  The inactive carrier stage may last for years or 
even lifetime. Patients in this stage can have spontaneous resolution of hepatitis B and develop HBsAb, but a portion of them may 
undergo spontaneous or immunosuppression-induced reactivation of chronic hepatitis, featuring elevated ALT, high level of DNA, 
moderate to severe liver histological activity, and with or without HBeAg seroreversion.  
5.  Clinical Spectrum of HBV Infection 
Primary Infection –Subclinical Infection and Acute hepatitis B.  Majority of HBV infection in children are subclinical 
versus those in adults, about 30% to 50% develop acute icteric hepatitis.  Those who recover should acquire lifelong immunity.  
However, a subset of patients will be chronically infected and very few patients (0.1% - 0.5%) can develop fulminant hepatitis.  In 
primary infection, HBsAg becomes detectable after 4 to 10 weeks of incubation period, followed by antibodies against the core 
antigen (HBcAb) in IgM form during early period [2].  Viremia is well established by the time HBsAg is detected (usually from 
10^9 to 10^10 per milliliter) [12].  Circulating HBeAg becomes detectable in most cases.  When liver injury occurs in acute 
infection, alanine aminotransferase levels do not increase until after viral infection is well established, reflecting the time required to 
generate the T-cell-mediated immune response that triggers liver injury.  Once this response has commenced, viral titer in blood and 
liver begins to drop.  With clearance of the infection, HBsAg and HBeAg disappear, and free HBsAb become detectable.  Presence 
of HBsAg, HBeAg, and high DNA level for greater than 6 months implies progression to chronic infection.  When persistent 
infection establishes, the serology markers like HBeAg, HBeAb and HBsAb can be positive or negative except HBsAg and HBcAb 
(IgG form) remain positive.  
HBeAg positive chronic hepatitis B. Age at the time of infection is a strong determinant of chronicity, the earlier the 
acquisition of infection, the higher probability of developing chronic infection.  Levels of viremia in chronic infection are generally 
significantly lower than during primary infection.  In adult acquired disease, the early phase of infection often is accompanied by 
significant disease activity with elevated ALT levels versus those who acquired the infection perinatally usually have normal ALT 
levels.  Many patients with perinatal infection enter the immunoactive phase and develop HBeAg positive chronic hepatitis with 
elevated ALT levels only after 10-30 years of infection [13].  A key event in natural history of progression is HBeAg seroconversion 
to HBeAb with marked reduction of HBV replication followed by gradual histological improvement [14].  In studies, the observed 
clearance of HBeAg is about 50% and 70% within 5 and 10 years of diagnosis respectively [9].  Most studies found the mean annual 
rate of spontaneous seroconversion is 8% to 15% in individuals with active liver disease, but those with normal ALT levels tend to 
have smaller annual conversion rate of 2% to 5%.   
HBeAg negative chronic hepatitis B. A proportion of patients who undergo HBeAg seroconversion demonstrate a recurrence 
of high HBV DNA levels and intermittent or persistent ALT level elevations.  These individuals have a naturally occurring mutant 
form of HBV that does not produce HBeAg, due to a mutation in the precore or core promoter region. Most frequent precore 
mutation is a G-A change at nucleotide 1896 (G1896A) which creates a stop codon and results in loss of HBeAg synthesis; the most 
common core promoter mutation involves a 2 nucleotide substitution at nucleotide 1762 and 1764 [15].  HBeAg-negative carriers 
are a heterogeneous group and most of them have low viral DNA levels, relatively normal levels of alanine aminotransferase, and a 
fair prognosis.  However, in Asia, Middle East, Mediterranean basin and southern Europe, about 15% to 20% of these carriers have 
elevated alanine aminotransferase and viral DNA [16].  HBeAg-negative chronic hepatitis B (precore mutant) emerges as the 
predominant species during the course of typical HBV infection with wild-type virus and is selected during the immune clearance 
phase (HBeAg seroconversion) [17].  The development of HBeAg-negative chronic hepatitis B can occur either close to HBeAg 
seroconversion or decades later.  There are 2 main patterns of disease activity in this subgroup of patients:  30%-40% of patients 
experience persistent elevated ALT levels (3-4 folds) and the remaining 60%-70% patients can have erratic ALT patterns with 
frequent flares.  Sustained spontaneous remission is rare (6% to 15%) in these individuals, and spontaneous HBsAg clearance is only 
about 0.5% per year [18]; hence, long-term prognosis is poorer among HBeAg-negative individuals than compare with their 
counterparts who are HBeAg-positive.   
Inactive HBsAg carrier state.  Inactive HBsAg carrier state is diagnosed by HBeAg negativity with anti-HBe positivity, 
undetectable or low HBV DNA level, repeatedly normal ALT, and normal or minimal histological evidence of damage [19].  The 
prognosis of the inactive carrier is generally good and well supported by long-term follow-up studies [20, 21, 22].  An estimated 
20% to 30% of HBsAg carriers may develop reactivation of hepatitis B with elevation of biochemical levels, high serum DNA level 
with or without sero-reversion to HBeAg.  Recurrent episodes of reactivation or sustained reactivation can occur and contribute to 
progressive liver disease and decompensation.  Frequently, HBV reactivation is usually asymptomatic, but it may mimic acute viral 
hepatitis.  On the other hand, some carriers eventually become HBsAg negative and develop HBsAb.  It is reported that the 
incidence of delayed HBsAg clearance is close to 1% to 2% per year in Western countries, but only 0.05% to 0.8% per year in 
endemic areas where infection was often acquired during childhood.  Apparently, women and older carriers have higher clearance of 
HBsAg.  Reactivations of HBV replication in patients who receive immunosuppressive therapy or cytotoxic chemotherapy have 
been reported in the range of 20% to 50% in chronic carriers [23, 24]; from experience, the combined use of corticosteroid in 
chemotherapies significantly increases the risk of reactivation [23].  However, these flares in the immunosuppressed individuals 
rarely result in significant hepatic decompensation. 
6.  Long-term Sequelae of Chronic Hepatitis B 
Cirrhosis 
Following the diagnosis of chronic hepatitis B, the survivals in these patients are estimated to be 100% at 5 years.  However, 
cirrhosis and hepatoma are two major long-term complications of chronic HBV infection that significantly increases morbidity and 
mortality.  In patients without cirrhosis, if untreated, the incidence of liver related death is low and ranges from 0 to 1.06 per 100 
person years.  The mortality rate at 5 years is 16% for those with compensated cirrhosis and is 65% to 86% for decompensated 
cirrhosis [25, 26].  In untreated individuals with predominantly HBeAg positive chronic hepatitis B, the incidence of cirrhosis ranges Int. J. Med. Sci. 2005 2(1) 
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from 2 to 5.4 per 100 person years with a 5-year cumulative incidence of cirrhosis of 8% to 20% [9].  A higher rate of cirrhosis has 
been reported in HBeAg-negative as compared to HBeAg-positive patients.  Also, older age and persistent viral replication are 
predictors for development of cirrhosis as well as mortality.  Genotype C is associated with a higher risk of cirrhosis than genotype 
B based on studies in Asian patients [27].  The presence of any other independent hepatotoxic factors such as alcohol ingestion, 
HCV co-infection can contribute to progression to cirrhosis.  Once cirrhosis is established, individuals can decompensate over time.  
In the EUROHEP cohort study, the 5-year cumulative incidence of hepatic decompensation was 16%, the incidence per 100 person 
years was 3.3 and the mean interval between the time of diagnosis of cirrhosis and the onset of first episode of decompensation was 
31 months (range 6-109) [28].  After decompensation, the survival drops to 55% to 70% at 1 year and to 14% to 28% at 5 years; 
Interestingly, an improvement in liver function activity has been observed in those individuals who subsequently lose their HBsAg 
positivity. 
Hepatocellular Carcinoma 
The development of hepatocellular carcinoma (HCC) and liver failure are main cause of death from chronic hepatitis B.  
Various factors involving the host and the virus may contribute to the development of hepatocellular carcinoma (Table 2).  It is 
estimated that over 500,000 people die each year from the consequence of HBV infection [9].  HCC incidence is three to six times 
higher in males than in females, suggesting a tumorigenic effect of androgens [10, 29].  Several studies have indicated that older age 
(>45 years) is an important determinant of HCC, this may either reflect a longer duration of viral infection and liver disease or age 
may be an independent risk factor.  Having a first degree relative with HCC, the presence of cirrhosis, and reversion activity are all 
thought to contribute to HCC development [10, 29, 30, 31].  Chronically infected subjects have a 100 times increased risk of 
hepatocellular carcinoma compare with non-carriers [20].  A recent study suggested positive HBsAg increased one’s risk of 
developing HCC by 10 folds, and with positive HBeAg, HCC is significantly increased by 60 folds.  Moreover, a detectable HBV 
DNA level yields a 4 fold increase risk of HCC [32].  The additional use of alcohol, consumption of aflatoxin in diet and co-
infection with HCV or HDV are independent factors for HCC in HBV infected patients.  Unlike hepatitis C, development of HCC in 
hepatitis B patients does not require preceding cirrhosis.  Hence, it is advocated that all HBV infected patients, regardless of 
cirrhosis status, should get screening for HCC every 6 months with alpha-fetoprotein (AFP) and liver sonogram.  Currently, there is 
no consensus as to when such screening should commence, but it is reasonable to start screening immediately once these patients 
seek medical attention.   
Table 2. Independent Risk Factors for the Development of HCC in HBV infection 
 
7.  Conclusion  
It has been encouraging to witness the recent discoveries in HBV infection 
with insights into the existence of genotype subgroups, mutant variants, 
knowledge regarding host, viral and environmental factors on the disease course, 
as well as advances in new treatment modalities.  However, despite the much 
progress in understanding the natural history of HBV infection, we still have a 
long way to go before we can conquer hepatitis B infection.  For instance, more 
studies are needed to clarify whether there is an association between genotype, 
mutant variants and the development of hepatocellular carcinoma.  In the 
HBeAg-positive subgroup, there still lacks a consensus on how to manage these 
patients when they present with signs of mild liver disease activity with alanine 
aminotransferase less than 2 fold increase; future studies with longer follow-up 
may help us gain knowledge about the HBV behavior in these individuals.  There is much more to be understood about mutations 
and their impacts on the clinical course and long-term outcome of hepatitis B infection.  For instance, it has been suggested that 
mutations can arise from vaccine-induced antibodies and this renders the immune response generated by the vaccination ineffective.  
Therefore, mutations may play a key role in the difficulties of managing hepatitis B infection.  Hence, further research and 
understanding in this sector may bring exciting new information and better understanding of the natural history of HBV and 
supplement our existing armamentarium to combat this persistent worldwide prevalent disease.    
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Figures 
Figure 1.   Stages of HBV infection based on virus-host interaction. In persistent infected patients, the stages of immune tolerance 
and immune clearance clinically present as HBeAg positive chronic hapatitis B. The stage of inactive phase clinically presents as 
HBsAg carrier. * During the  stage of reactivation, majority of patients remain HBeAg negative with positive HBeAb and their 
clinical presentation can be HBeAg negative chornic hepatitis B, but some patients may have seroreversion of HBeAg and present as 
HBeAg positive chornic hepatitis B. 
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